Autolus Therapeutics (AUTL) Profit After Tax (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Profit After Tax data on file, last reported at -$90.3 million in Q4 2025.

• Quarterly Profit After Tax fell 225.58% year-over-year to -$90.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$293.3 million (down 32.82% YoY) and the FY2025 annual result came in at -$287.5 million, down 30.2% from the prior year.
• Profit After Tax declined to -$90.3 million in Q4 2025, from -$84.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$18.3 million in Q4 2022 to a low of -$90.3 million in Q4 2025.
• A 5-year average of -$52.8 million and a median of -$49.8 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax sank 322.14% — and 2024, when it soared 64.06%.
• Tracing AUTL's Profit After Tax over 5 years: stood at -$40.7 million in 2021, then jumped by 55.1% to -$18.3 million in 2022, then slumped by 322.14% to -$77.2 million in 2023, then soared by 64.06% to -$27.7 million in 2024, then sank by 225.58% to -$90.3 million in 2025.
• The last three Profit After Tax figures came in at -$90.3 million (Q4 2025), -$84.9 million (Q3 2025), and -$47.9 million (Q2 2025), per Business Quant data.